Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Generics Players Dominating New OTC Launches In Germany

An analysis by Sempora Consulting of the German OTC market in 2018 shows that generic products dominate new OTC product launches.
Health OTC Drugs

Industry Pact Aligns Canadian Prices To International Levels

An agreement between industry and authorities in effect from April last year is already having a major effect in ensuring Canadian generics prices are similar to those in other developed markets, an official report shows.

Canada Pricing Debate

Oxytetracycline Prices Double As Hydrocortisone Plunges In UK

July saw UK generic trade price rises peak at a 100% increase for oxytetracycline 250mg tablets, while hydrocortisone 20mg tablets saw their average price plummet by two-thirds, according to the latest figures from WaveData.

United Kingdom Pricing Strategies

No-Deal Brexit May Lead To A Fragmented Market

Panellists at the UK’s Westminster Health Forum conference on Biosimilars in the NHS united over concerns of a no-deal Brexit and what it would mean for generics and biosimilars producers.

Biosimilars United Kingdom

GDUFA Report Sheds Light On Effectiveness And Uptake

The latest GDUFA science and research findings have been reported by the FDA. 

Regulation Research & Development

UK Biosimilar Market Grows As NHS Uptake Improves

The UK’s market of 65m patients is gearing up for several new biosimilars to hit the market, with 15 biologic brands set to lose exclusivity in Europe over the next four to five years. However, challenges remain.

Biosimilars United Kingdom
See All
UsernamePublicRestriction

Register